ClinicalTrials.gg

Program

XH-S003 Capsule

Also written as “XH-S003 (A)” and “XH-S003”.

Its studies are mostly in Glomerulonephritis, IGA · Hemoglobinuria, Paroxysmal, led by Fosun Pharma.

Furthest: phase 2, since Feb 27, 20254 company-led studies, 1 open or runningNext primary completion: Sep 30, 2029

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma41 open or runningphase 2since Feb 27, 2025Jul 7, 2023Sep 30, 2029NCT07657052

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 7, 2023First study: phase 1 study in HealthyFirst studyNCT05946876 · 77 enrolled · Australia
  2. Feb 15, 2024Phase 1 study in Healthy AdultsNCT06272747 · 36 enrolled · China
  3. Feb 27, 2025Phase 2 study in Glomerulonephritis, IGANCT07634744 · 25 enrolled · China
  4. May 29, 2026No phase study in Hemoglobinuria, ParoxysmalNCT07657052 · 26 planned · China

Ahead

  1. Sep 30, 2029Primary completion: no phase study in Hemoglobinuria, ParoxysmalNCT07657052

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07657052Hemoglobinuria, Paroxysmal · China–By invitationSep 30, 202926
NCT07634744Glomerulonephritis, IGA · China2CompletedApr 23, 202625
NCT06272747Healthy Adults · China1CompletedJul 30, 202436
NCT05946876Healthy · Australia1CompletedJul 11, 202477

How it is read

Names in the registry

  • “XH-S003 Capsule”, 2 entries
  • “XH-S003 (A)”, 1 entry
  • “XH-S003”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.